Harrow Health

HROWPre-clinical

Harrow Health is an integrated eyecare company with a mission to address unmet needs in ophthalmology through a diversified business model encompassing proprietary pharmaceuticals, non-sterile compounding, and sterile compounding. The company has achieved commercial success with several FDA-approved products and maintains a pipeline of development-stage candidates. Its strategic direction involves leveraging its ImprimisRx platform for distribution while advancing its proprietary pipeline through internal development and acquisitions.

Market Cap

$1.2B

Employees

200-500

Focus

Biotech

HROW · Stock Price

USD 33.28+26.27 (+374.75%)

Historical price data

AI Company Overview

Technology Platform

Integrated ophthalmic pharmaceutical model combining a proprietary and non-proprietary drug development engine with a nationwide FDA-registered 503B compounding pharmacy and distribution platform (ImprimisRx).

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
Ergocalciferol	Tuberculosis	Pre-clinical

Funding History

Total raised: $25M

PIPE$25MUndisclosedAug 15, 2022

IPOUndisclosedUndisclosedJul 15, 2014

Opportunities

Significant growth opportunity lies in the rapid adoption of IHEEZO as a new standard of care for ocular anesthesia in cataract surgery.

Further upside exists from optimizing the recently acquired Novartis portfolio and leveraging the ImprimisRx distribution channel to launch future proprietary products.

Expansion into adjacent ophthalmic subspecialties like retina presents a longer-term opportunity.

Risk Factors

Key risks include regulatory scrutiny of the compounding pharmacy business model, integration challenges from recent acquisitions, clinical failure of pipeline candidates, intense competition from larger pharmaceutical companies, and exposure to generic pricing pressure on mature products.

Competitive Landscape

Harrow competes with large ophthalmic pharma (Novartis/Alcon, AbbVie, Bausch + Lomb), generic manufacturers, and specialty compounding pharmacies. Its primary differentiation is its integrated commercial model via ImprimisRx, which provides direct physician access and a lower-cost launch platform for its proprietary products compared to traditional pharma sales forces.

Publications

Patents

Pipeline